{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:24:11Z","timestamp":1791991451315,"version":"4.4.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Department of Laboratory Medicine and Pathology"},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,27]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. MN is characterized by subepithelial accumulation of immune complexes along the glomerular basement membrane. The immune complexes are composed of immunoglobulin G and a target antigen. PLA2R is the target antigen in approximately 60% of MN cases, and MN is traditionally classified as PLA2R-positive or PLA2R-negative MN. Over the last 7\u00a0years, additional target antigens have been identified, which have specific disease associations, distinctive clinical and pathologic findings, and therapeutic implications. The newly discovered target antigens include NELL1, EXT1\/EXT2, NCAM1, SEMA3B, PCDH7, FAT1, CNTN1, NTNG1, PCSK6 and NDNF. To group all these antigens into a generic \u2018PLA2R-negative\u2019 MN group is imprecise and un-informative. We propose a logical approach for detection of the target antigen which includes (i) currently available serology-based testing to detect anti-PLA2R and anti-THSD7A antibodies; and (ii) kidney biopsy testing to detect the target antigens. Determination of the antigen on kidney biopsy can be done by immunohistochemistry or immunofluorescence studies. Alternatively, laser capture microdissection (LCM) of glomeruli followed by mass spectrometry (MS) can be used to identify a target antigen. LCM\/MS has the advantage of being a one-stop test and is particularly useful for detection of rare target antigens. At the current time, while it is possible to detect the newer antigens by immunohistochemistry\/immunofluorescence\/LCM\/MS, serology-based tests to detect serum antibodies to the new antigens are not yet available. It is critical that serology-based tests should be developed not just for accurate diagnosis, but as a guide for treatment. We review the current methodology and propose an algorithm for diagnosis and detection of target antigens in MN that may shape the current practice in the future. Membranous nephropathy (MN) results from accumulation of subepithelial immune complexes along the glomerular basement membrane.PLA2R is the most common target antigen, but newly discovered target antigens have filled the void of PLA2R-negative MN.MN associated with the newly discovered target antigens have distinctive clinical and pathologic findings, treatment and prognostic implications. These include NELL1, EXT1\/EXT2, NCAM1, PCDH7, SEMA3B, CNTN1, FAT1, NDNF and PCSK6.Immunohistochemistry\/immunofluorescence methodology is currently in use for detecting target antigens in kidney biopsy tissue, although we anticipate laser capture microdissection of glomeruli followed by mass spectrometry will become available soon.Serologic testing is currently available for only detecting antibodies to PLA2R and THSD7A. It is critical that serologic tests become available for detecting antibodies to the newly discovered antigens.<\/jats:p>","DOI":"10.1093\/ndt\/gfad227","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T02:13:02Z","timestamp":1697854382000},"page":"600-606","source":"Crossref","is-referenced-by-count":57,"title":["Membranous nephropathy\u2014diagnosis and identification of target antigens"],"prefix":"10.1093","volume":"39","author":[{"given":"Sanjeev","family":"Sethi","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C","family":"Fervenza","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"key":"2024032707111364200_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2023.08.006","article-title":"Mayo Clinic Consensus Report on Membranous Nephropathy: proposal for a novel classification","author":"Sethi","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"2024032707111364200_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"2024032707111364200_bib4","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"2024032707111364200_bib5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/exostosin 2\u2013associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2024032707111364200_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib7","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B\u2013associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.kint.2020.09.016","article-title":"Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis","volume":"100","author":"Caza","year":"2021","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib9","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1681\/ASN.2020081165","article-title":"Protocadherin 7-associated membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2024032707111364200_bib10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1681\/ASN.2021111488","article-title":"Hematopoietic stem cell transplant-membranous nephropathy is associated with protocadherin FAT1","volume":"33","author":"Sethi","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2024032707111364200_bib11","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1681\/ASN.2020101395","article-title":"Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy","volume":"32","author":"Al-Rabadi","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2024032707111364200_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1681\/ASN.0000000000000061","article-title":"Membranous nephropathy in syphilis is associated with neuron-derived neurotrophic factor","volume":"34","author":"Sethi","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2024032707111364200_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.kint.2023.04.006","article-title":"Proprotein convertase subtilisin\/kexin type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib14","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.kint.2021.08.014","article-title":"Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy","volume":"100","author":"Le Quintrec","year":"2021","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.kint.2023.01.001","article-title":"Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry","volume":"103","author":"Caza","year":"2023","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1681\/ASN.2020071082","article-title":"New \u2018antigens\u2019 in membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2024032707111364200_bib17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.kint.2023.01.003","article-title":"Mapping antigens of membranous nephropathy: almost there","volume":"103","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib18","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1681\/ASN.2022050608","article-title":"Netrin G1 is a novel target antigen in primary membranous nephropathy","volume":"33","author":"Reinhard","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2024032707111364200_bib19","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/ckj\/sfab069","article-title":"Membranous nephropathy: a single disease or a pattern of injury resulting from different diseases","volume":"14","author":"Sethi","year":"2021","journal-title":"Clin Kidney J"},{"key":"2024032707111364200_bib20","article-title":"From patterns to proteins: mass spectrometry comes of age in glomerular disease","author":"Sethi","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2024032707111364200_bib21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/ndt\/gfac177","article-title":"The risks associated with percutaneous native kidney biopsies: a prospective study","volume":"38","author":"Andrulli","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2024032707111364200_bib22","doi-asserted-by":"crossref","first-page":"e104936","DOI":"10.1371\/journal.pone.0104936","article-title":"The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One"},{"key":"2024032707111364200_bib23","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient's care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet"},{"key":"2024032707111364200_bib24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2024032707111364200_bib25","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.2215\/CJN.07210810","article-title":"Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy","volume":"6","author":"Hofstra","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024032707111364200_bib26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.autrev.2015.10.004","article-title":"Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)","volume":"15","author":"Radice","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2024032707111364200_bib27","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2024032707111364200_bib28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000437236","article-title":"Anti-PLA2R antibodies as a prognostic factor in PLA2R-related membranous nephropathy","volume":"42","author":"Timmermans","year":"2015","journal-title":"Am J Nephrol"},{"key":"2024032707111364200_bib29","doi-asserted-by":"crossref","first-page":"e110681","DOI":"10.1371\/journal.pone.0110681","article-title":"PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system","volume":"9","author":"Hoxha","year":"2014","journal-title":"PLoS One"},{"key":"2024032707111364200_bib30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib31","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2024032707111364200_bib32","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2024032707111364200_bib33","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.2215\/CJN.00440113","article-title":"American Society of Nephrology quiz and questionnaire 2012: glomerulonephritis","volume":"8","author":"Fervenza","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024032707111364200_bib34","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/ndt\/gfs439","article-title":"Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy","volume":"28","author":"Svobodova","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2024032707111364200_bib35","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/ki.2015.34","article-title":"Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up","volume":"87","author":"van de Logt","year":"2015","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib36","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMc1011678","article-title":"PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy","volume":"364","author":"Debiec","year":"2011","journal-title":"N Engl J Med"},{"key":"2024032707111364200_bib37","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/ki.2015.310","article-title":"Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy","volume":"88","author":"Ramachandran","year":"2015","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.kint.2022.11.004","article-title":"False-positive anti-PLA2R ELISA testing in patients with diabetes mellitus","volume":"103","author":"Caza","year":"2023","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.kint.2022.09.011","article-title":"False positivity for PLA2R1 antibody measured by ELISA in a nephrotic patient with no membranous nephropathy","volume":"103","author":"Hoxha","year":"2023","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib40","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib41","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2215\/CJN.05480421","article-title":"Noninvasive diagnosis of PLA2R-associated membranous nephropathy: a validation study","volume":"16","author":"Bobart","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024032707111364200_bib42","doi-asserted-by":"crossref","first-page":"890","DOI":"10.34067\/KID.0003262020","article-title":"Kidney biopsy is required for nephrotic syndrome with PLA2R+ and normal kidney function: the con view","volume":"1","author":"Bobart","year":"2020","journal-title":"Kidney360"},{"key":"2024032707111364200_bib43","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024032707111364200_bib44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"key":"2024032707111364200_bib45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad227\/55142375\/gfad227.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/4\/600\/57094268\/gfad227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/4\/600\/57094268\/gfad227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T08:10:14Z","timestamp":1711527014000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/39\/4\/600\/7325993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,10,20]]},"published-print":{"date-parts":[[2024,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad227","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2023,10,20]]}}}